A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

BACKGROUNDS: As a new oral chemotherapy drug, TAS-102 is currently recommended as the third-line treatment for metastatic colorectal cancer (mCRC). Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. Here, we eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaochen, Qiu, Huafeng, Chen, Yunwang, Wang, Mingxing, Zhu, Pengfei, Pan, Shuangyue, Deng, Yaya, Yang, Liu, Chen, Zheling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637322/
https://www.ncbi.nlm.nih.gov/pubmed/34868908
http://dx.doi.org/10.3389/fonc.2021.690515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637322/
https://www.ncbi.nlm.nih.gov/pubmed/34868908
http://dx.doi.org/10.3389/fonc.2021.690515

Ejemplares similares